Clinical Trial Update: CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids [Phase 2]

View source ↗

Summary

A Phase 2 trial of CYT003 in patients with mild-to-moderate allergic asthma not adequately controlled on inhaled corticosteroids has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CYT003

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Asthma | Phase 2 | Status: WITHDRAWN